racepinephrine has been researched along with Bronchiolitis, Viral in 3 studies
Racepinephrine: A racemic mixture of d-epinephrine and l-epinephrine.
4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol : A catecholamine in which the aminoethyl side-chain is hydroxy-substituted at C-1 and methylated on nitrogen.
Bronchiolitis, Viral: An acute inflammatory disease of the lower RESPIRATORY TRACT, caused by paramyxoviruses, occurring primarily in infants and young children; the viruses most commonly implicated are PARAINFLUENZA VIRUS TYPE 3; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; and METAPNEUMOVIRUS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Levin, DL | 1 |
| Garg, A | 1 |
| Hall, LJ | 1 |
| Slogic, S | 1 |
| Jarvis, JD | 1 |
| Leiter, JC | 1 |
| Grewal, S | 1 |
| Ali, S | 1 |
| McConnell, DW | 1 |
| Vandermeer, B | 1 |
| Klassen, TP | 1 |
| Barr, FE | 1 |
| Patel, NR | 1 |
| Newth, CJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Nebulized 3% Hypertonic Saline With Salbutamol in the Treatment of Acute Bronchiolitis in Pediatric Hospital[NCT02233985] | Phase 4 | 64 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Nebulized Hypertonic Saline for Acute Bronchiolitis in the Emergency Department[NCT01247064] | Phase 4 | 62 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Each patient record the time of entry and measured the total hospital stay time in hours, recording the time of discharge to determine the total stay in hours. The hospital stay will be evaluated in hours. Staying hospitalized until they had mild respiratory stage scale scores for at least 2 hrs. (NCT02233985)
Timeframe: Throughout the stay for each patient until discharge. Follow-up will be continued for a period of 30 days in which they may present readmissions, complications or adverse effects.
| Intervention | hours (Median) |
|---|---|
| Hypertonic Saline Solution 3% (SHS 3%) | 8 |
| Saline Solution 0.9% (SS 0.9%) Group | 39.3 |
It is a validated clinical scale, sufficiently reliable measure of Severity of the respiratory distress. It consists of the summation score of the sibilance / crackling parameters (the largest of them), respiratory effort, pulmonary air inlet, oxygen saturation, heart rate and breathing rate. It is stratified into 3 levels of severity: mild from 0 to 5 points, moderate from 6 to 10 and severe from 10 to 16. (NCT02233985)
Timeframe: Basal, 30 minutes after the end of the first 3 continuous nebulization sessions, at 4 hours, 8 hours and every 24 hours during the entire hospital stay
| Intervention | units on a scale (Median) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Basal | 30 minutes | 4 hours | 8 hours | 12 hours | 24 hours | 48 hours | 72 hours | 96 hours | 120 hours | 144 hours | 196 hours | |
| Hypertonic Saline Solution 3% (HSS 3%) Group | 8 | 6 | 5 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Saline Solution 0.9% (SS 0.9%) Group | 8 | 8 | 8 | 8 | 7 | 7 | 7 | 6 | 5 | 3 | 6 | 4 |
(NCT01247064)
Timeframe: Baseline and 1 hour
| Intervention | percent (Mean) |
|---|---|
| Nebulized 3% Saline | 1.1 |
| Nebulized 0.9% Normal Saline | 0.1 |
(NCT01247064)
Timeframe: 1 hour
| Intervention | percentage of participants (Number) |
|---|---|
| Nebulized 3% Saline | 50 |
| Nebulized 0.9% Normal Saline | 54.8 |
(NCT01247064)
Timeframe: 1 day
| Intervention | percentage of participants (Number) |
|---|---|
| Nebulized 3% Saline | 71 |
| Nebulized 0.9% Normal Saline | 64.5 |
The Respiratory Assessment Change Score (RACS) assesses change in respiratory status using the change in the Respiratory Distress Assessment Instrument (RDAI) and a standardized change in respiratory rate, with points being assigned by change increments of 10%. Thus, a change in respiratory rate of ≤5% from baseline counted as a change of 0 units, decrease/increase of 6% to 15% counted as improvement/deterioration of 1 unit, etc. The overall RACS is the arithmetic sum of the RDAI change and the standardized respiratory rate change between assessments with a decrease in RACS signifying improvement. (NCT01247064)
Timeframe: Baseline and 1 hour
| Intervention | units on a scale (Mean) |
|---|---|
| Nebulized 3% Saline | -1.5 |
| Nebulized 0.9% Normal Saline | -4 |
(NCT01247064)
Timeframe: Baseline and 1 hour
| Intervention | breaths per minute (Mean) |
|---|---|
| Nebulized 3% Saline | -1.8 |
| Nebulized 0.9% Normal Saline | -9.8 |
2 trials available for racepinephrine and Bronchiolitis, Viral
| Article | Year |
|---|---|
A prospective randomized controlled blinded study of three bronchodilators in infants with respiratory syncytial virus bronchiolitis on mechanical ventilation.
Topics: Airway Resistance; Albuterol; Bronchiolitis, Viral; Bronchodilator Agents; Epinephrine; Female; Huma | 2008 |
A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department.
Topics: Acute Disease; Age Factors; Asthma; Bronchiolitis, Viral; Bronchodilator Agents; Double-Blind Method | 2009 |
A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department.
Topics: Acute Disease; Age Factors; Asthma; Bronchiolitis, Viral; Bronchodilator Agents; Double-Blind Method | 2009 |
A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department.
Topics: Acute Disease; Age Factors; Asthma; Bronchiolitis, Viral; Bronchodilator Agents; Double-Blind Method | 2009 |
A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department.
Topics: Acute Disease; Age Factors; Asthma; Bronchiolitis, Viral; Bronchodilator Agents; Double-Blind Method | 2009 |
1 other study available for racepinephrine and Bronchiolitis, Viral
| Article | Year |
|---|---|
The pharmacologic mechanism by which inhaled epinephrine reduces airway obstruction in respiratory syncytial virus-associated bronchiolitis.
Topics: Administration, Inhalation; Adrenergic Agonists; Adrenergic beta-Antagonists; Bronchiolitis, Viral; | 2000 |